ARTICLE | Company News
Galapagos, AbbVie deal
September 30, 2013 7:00 AM UTC
The companies partnered to develop and commercialize oral potentiators and correctors of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene including G551D and delta F50...